The tripling of the ATM capacity to $150M, combined with the same-day $200M shelf filing, signals aggressive capital raising. Monitor the pace of ATM sales in future filings and any use of the new shelf for additional offerings. The company's history of frequent equity raises and negative retained earnings suggests ongoing cash burn.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 19 $7.31entry
- T+1 · 2d ago −5.47%α −1.83% · $6.91
- T+5 · in 5d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
ClearPoint Neuro amended its existing ATM equity offering sales agreement with Stifel, increasing the aggregate sales proceeds limit from $50M to $150M. The company has already sold $22.5M under the original agreement, leaving $27.5M available under the current prospectus supplement. The amendment was filed on the same day as a $200M universal shelf registration (including a $100M ATM program), signaling a significant increase in potential equity dilution.
Key Facts
- ATM equity offering sales agreement amended to increase aggregate proceeds from $50M to $150M
- Company has sold approximately $22.5M of shares under the original agreement to date
- Approximately $27.5M remains available under the current ATM prospectus supplement
- Agent commission is 3.0% of gross sales price
- Filed same day as S-3 shelf registration for up to $200M in securities including a $100M ATM program
- Company has a $266M market cap, making the $150M ATM limit more than half of current market value
Financial Impact
Potential equity dilution of up to $150M (56% of current $266M market cap) through ATM sales, with $22.5M already sold and $27.5M currently available
Risk Factors
- Significant dilution risk as ATM capacity is 56% of current market cap
- Same-day shelf registration compounds potential dilution beyond the ATM alone
- Frequent capital raises (4 offerings in 24 months) indicate structural cash needs
- No stated use of proceeds or business rationale for the increased capacity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-467272 |
| Document: clpt-ex1_1.htm | 0001193125-26-467272 |
| Document: 0001193125-26-467272-index-headers.html | 0001193125-26-467272 |
| Document: 0001193125-26-467272-index.html | 0001193125-26-467272 |
| Document: 0001193125-26-467272.txt | 0001193125-26-467272 |
Track record
8 reports on CLPT
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +18.71% at T+5 after the Oct 28, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 18, 20263d ago 8-K Bearish 5/10 Viewing Entry $7.31 to $6.91 Now $6.91 +5.47% ▲ +5.47% +1.83% vs SPY
- Nov 18, 20263d ago S-3 Bearish 5/10 Entry $7.31 to $6.91 Now $6.91 +5.47% ▲ +5.47% +1.83% vs SPY
- Nov 16, 20265d ago Institutional Cluster Mixed 3/10 Entry $8.30 to $7.86 Now $6.91 −16.75% ▼ −5.30% −4.29% vs SPY
- Nov 3, 202618d ago SC 13G/A Bearish 5/10 Entry $10.16 to $8.69 Now $6.91 +31.99% ▲ +14.47% +10.06% vs SPY
- Oct 28, 202624d ago 8-K Bearish 6/10 Entry $10.69 to $10.67 Now $6.91 +35.36% ▲ +0.19% −1.59% vs SPY
- May 21, 202626w ago 8-K Neutral 3/10 Entry $11.44 to $11.82 Now $6.91 −39.60% ▲ +3.32% +2.74% vs SPY
- May 20, 202626w ago 144 Neutral 2/10 Entry $11.70 to $11.44 Now $6.91 −40.94% ▼ −2.22% −2.67% vs SPY
- May 13, 202627w ago 8-K Mixed 5/10 Entry $12.77 to $12.77 Now $6.91 −45.89% · 0.00% −0.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers